JP2017530199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530199A5 JP2017530199A5 JP2017538172A JP2017538172A JP2017530199A5 JP 2017530199 A5 JP2017530199 A5 JP 2017530199A5 JP 2017538172 A JP2017538172 A JP 2017538172A JP 2017538172 A JP2017538172 A JP 2017538172A JP 2017530199 A5 JP2017530199 A5 JP 2017530199A5
- Authority
- JP
- Japan
- Prior art keywords
- purin
- cyclohexanecarboxamide
- ylamino
- chloro
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 chloro, iodo Chemical group 0.000 claims description 117
- 150000001875 compounds Chemical class 0.000 claims description 113
- 125000000217 alkyl group Chemical group 0.000 claims description 43
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 12
- 108091000080 Phosphotransferase Proteins 0.000 claims description 11
- 102000020233 phosphotransferase Human genes 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 102000001253 Protein Kinase Human genes 0.000 claims description 9
- 108060006633 protein kinase Proteins 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000003551 oxepanyl group Chemical group 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 claims description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 claims description 2
- QBCBXKOOFXNSLU-AMPCRFMZSA-N NC(=O)[C@@H]1CC[C@@H](CC1)N1C(NC2=CC=C(F)C=C2F)=NC2=CN=C(N[C@H]3CC[C@H](O)CC3)N=C12 Chemical group NC(=O)[C@@H]1CC[C@@H](CC1)N1C(NC2=CC=C(F)C=C2F)=NC2=CN=C(N[C@H]3CC[C@H](O)CC3)N=C12 QBCBXKOOFXNSLU-AMPCRFMZSA-N 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- VYOMWAWIBCGOKB-BJHJDKERSA-N chembl1950291 Chemical compound N1([C@H]2CC[C@H](CC2)C(N)=O)C2=NC(NC(C)C)=NC=C2N=C1NC1=C(F)C=C(F)C=C1F VYOMWAWIBCGOKB-BJHJDKERSA-N 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims 81
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical class OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 claims 14
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 12
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 150000007857 hydrazones Chemical class 0.000 claims 3
- GDLOOQFSFHLRKT-UHFFFAOYSA-N 1-methylcyclohexane-1-carboxamide Chemical compound NC(=O)C1(C)CCCCC1 GDLOOQFSFHLRKT-UHFFFAOYSA-N 0.000 claims 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005262 alkoxyamine group Chemical group 0.000 claims 2
- 150000001409 amidines Chemical class 0.000 claims 2
- 150000001540 azides Chemical class 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 2
- 150000002081 enamines Chemical class 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000012948 isocyanate Substances 0.000 claims 2
- 150000002513 isocyanates Chemical class 0.000 claims 2
- 150000002540 isothiocyanates Chemical class 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 150000002923 oximes Chemical class 0.000 claims 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- 150000003457 sulfones Chemical class 0.000 claims 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- 150000003949 imides Chemical class 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019182133A JP6987823B2 (ja) | 2014-10-06 | 2019-10-02 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
| JP2021195105A JP7196270B2 (ja) | 2014-10-06 | 2021-12-01 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
| JP2022199122A JP2023027269A (ja) | 2014-10-06 | 2022-12-14 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060339P | 2014-10-06 | 2014-10-06 | |
| US62/060,339 | 2014-10-06 | ||
| PCT/US2015/053941 WO2016057370A1 (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182133A Division JP6987823B2 (ja) | 2014-10-06 | 2019-10-02 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530199A JP2017530199A (ja) | 2017-10-12 |
| JP2017530199A5 true JP2017530199A5 (https=) | 2018-11-15 |
| JP6884701B2 JP6884701B2 (ja) | 2021-06-09 |
Family
ID=55632334
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538172A Active JP6884701B2 (ja) | 2014-10-06 | 2015-10-05 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
| JP2019182133A Active JP6987823B2 (ja) | 2014-10-06 | 2019-10-02 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
| JP2021195105A Active JP7196270B2 (ja) | 2014-10-06 | 2021-12-01 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
| JP2022199122A Pending JP2023027269A (ja) | 2014-10-06 | 2022-12-14 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182133A Active JP6987823B2 (ja) | 2014-10-06 | 2019-10-02 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
| JP2021195105A Active JP7196270B2 (ja) | 2014-10-06 | 2021-12-01 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
| JP2022199122A Pending JP2023027269A (ja) | 2014-10-06 | 2022-12-14 | 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9512124B2 (https=) |
| EP (2) | EP3822274B1 (https=) |
| JP (4) | JP6884701B2 (https=) |
| KR (2) | KR102504849B1 (https=) |
| CN (2) | CN107001372B (https=) |
| AR (2) | AR102171A1 (https=) |
| AU (2) | AU2015328414B2 (https=) |
| CA (1) | CA2963639C (https=) |
| CL (1) | CL2017000820A1 (https=) |
| CO (1) | CO2017003838A2 (https=) |
| CY (1) | CY1124173T1 (https=) |
| DK (1) | DK3204386T3 (https=) |
| EA (1) | EA201790779A1 (https=) |
| EC (1) | ECSP17026210A (https=) |
| ES (2) | ES2980464T3 (https=) |
| HR (1) | HRP20210656T1 (https=) |
| HU (1) | HUE054694T2 (https=) |
| IL (2) | IL251566B (https=) |
| LT (1) | LT3204386T (https=) |
| MX (2) | MX388321B (https=) |
| PL (1) | PL3204386T3 (https=) |
| PT (1) | PT3204386T (https=) |
| RS (1) | RS61884B1 (https=) |
| SG (2) | SG11201702759XA (https=) |
| SI (1) | SI3204386T1 (https=) |
| SM (1) | SMT202100302T1 (https=) |
| TW (1) | TW201629063A (https=) |
| WO (1) | WO2016057370A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388321B (es) | 2014-10-06 | 2025-03-19 | Signal Pharm Llc | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. |
| EP3233808B1 (en) | 2014-12-16 | 2021-07-14 | Signal Pharmaceuticals, LLC | Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CN107635993B (zh) | 2015-03-18 | 2020-05-22 | 百时美施贵宝公司 | 取代的三环杂环化合物 |
| ES2797685T3 (es) | 2015-03-18 | 2020-12-03 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF |
| WO2016149439A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Heterocyclic compounds useful as inhibitors of tnf |
| CA3208587A1 (en) | 2015-07-24 | 2017-02-02 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| BR112018001980A2 (pt) | 2015-08-03 | 2018-09-18 | Bristol Myers Squibb Co | compostos cíclicos úteis como moduladores de tnf alfa |
| RS62496B1 (sr) * | 2016-04-01 | 2021-11-30 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu |
| AU2017241837B2 (en) * | 2016-04-01 | 2021-07-22 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| CN109563095B (zh) * | 2016-06-02 | 2021-10-29 | 细胞基因公司 | 动物和人抗疟剂 |
| EP3464312A4 (en) * | 2016-06-02 | 2019-11-27 | Celgene Corporation | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS |
| MX2020003620A (es) * | 2017-10-04 | 2020-10-28 | Celgene Corp | Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida. |
| CN111417634A (zh) * | 2017-10-04 | 2020-07-14 | 细胞基因公司 | 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法 |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| CN114478326B (zh) * | 2022-01-21 | 2023-10-03 | 安徽宁亿泰科技有限公司 | 一种苯嘧磺草胺关键中间体的合成方法 |
| CN117964497B (zh) * | 2024-01-26 | 2026-03-31 | 江西凯信生物医药有限公司 | 一种3,3-二氟环戊胺盐酸盐的合成方法 |
| CN121758295A (zh) * | 2024-09-30 | 2026-03-31 | 青岛清原化合物有限公司 | 一种亚氨基芳基类化合物及中间体的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US7672705B2 (en) * | 2004-07-19 | 2010-03-02 | Resonant Medical, Inc. | Weighted surface-to-surface mapping |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7521446B2 (en) * | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US20090215744A1 (en) | 2005-11-18 | 2009-08-27 | Astrazeneca Ab | Solid Formulations |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| NZ598071A (en) | 2006-10-27 | 2013-08-30 | Signal Pharm Llc | Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds |
| WO2009130342A1 (es) | 2008-04-23 | 2009-10-29 | Farmasierra Manufacturing, S.L. | Formulación farmacéutica mejorada a base de ibuprofeno y codeína |
| US20130034495A1 (en) | 2009-12-09 | 2013-02-07 | Marie Georges Beauchamps | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US20160082015A1 (en) | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| MX388321B (es) | 2014-10-06 | 2025-03-19 | Signal Pharm Llc | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. |
| RS62496B1 (sr) | 2016-04-01 | 2021-11-30 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu |
-
2015
- 2015-10-05 MX MX2017004600A patent/MX388321B/es unknown
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 ES ES20214685T patent/ES2980464T3/es active Active
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active Active
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 SM SM20210302T patent/SMT202100302T1/it unknown
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko not_active Withdrawn
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en not_active Ceased
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
-
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
-
2017
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
-
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
-
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
-
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
-
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
-
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
-
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en not_active Abandoned
- 2023-03-09 AR ARP230100589A patent/AR128748A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530199A5 (https=) | ||
| JP2023027269A5 (https=) | ||
| RU2017121958A (ru) | Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью | |
| HRP20210656T1 (hr) | Supstituirani spojevi aminopurina, njihovi sastavi, te postupci liječenja istima | |
| RU2469032C2 (ru) | Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы | |
| JP2019505541A5 (https=) | ||
| JP2018522823A5 (https=) | ||
| AU2013305634B2 (en) | Novel 4,6-disubstituted aminopyrimidine derivatives | |
| JP2011518158A5 (https=) | ||
| AU2019201179A1 (en) | Therapeutically active compounds and their methods of use | |
| JP2016528201A5 (https=) | ||
| JP2018509418A5 (https=) | ||
| PH12014501561B1 (en) | Therapeutically active compounds and their methods of use | |
| JP2015529224A5 (https=) | ||
| CA2582029A1 (en) | Aryl nitrogen-containing bicyclic compounds and methods of use | |
| RU2004127925A (ru) | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек | |
| JP2018505898A5 (https=) | ||
| WO2017195216A4 (en) | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors | |
| RU2013108702A (ru) | Ингибиторы деметилазы lsd1 на основе арилциклопропиламина и их применение в медицине | |
| RU2013130925A (ru) | Оксимовые соединения в качестве средств для повышения уровня холестерина высокой плотности | |
| JP2006509748A5 (https=) | ||
| JP2013505903A5 (https=) | ||
| JP2007519754A5 (https=) | ||
| JP2013510876A5 (https=) | ||
| JP2018502912A5 (https=) |